JP2020507760A - 方法、アレイ、およびそれらの使用 - Google Patents

方法、アレイ、およびそれらの使用 Download PDF

Info

Publication number
JP2020507760A
JP2020507760A JP2019541330A JP2019541330A JP2020507760A JP 2020507760 A JP2020507760 A JP 2020507760A JP 2019541330 A JP2019541330 A JP 2019541330A JP 2019541330 A JP2019541330 A JP 2019541330A JP 2020507760 A JP2020507760 A JP 2020507760A
Authority
JP
Japan
Prior art keywords
biomarkers
pancreatic cancer
weeks
sample
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019541330A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020507760A5 (enExample
Inventor
カール・ボーレベック
リンダ・デクスリン・メルビー
アンドレアス・ニーベリ
クリステル・ヴィングレン
Original Assignee
イミュノヴィア・アーベー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イミュノヴィア・アーベー filed Critical イミュノヴィア・アーベー
Publication of JP2020507760A publication Critical patent/JP2020507760A/ja
Publication of JP2020507760A5 publication Critical patent/JP2020507760A5/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2019541330A 2017-01-31 2018-01-31 方法、アレイ、およびそれらの使用 Pending JP2020507760A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1701572.8A GB201701572D0 (en) 2017-01-31 2017-01-31 Methods, arrays and uses thereof
GB1701572.8 2017-01-31
PCT/EP2018/052423 WO2018141804A1 (en) 2017-01-31 2018-01-31 Methods, arrays and uses thereof

Publications (2)

Publication Number Publication Date
JP2020507760A true JP2020507760A (ja) 2020-03-12
JP2020507760A5 JP2020507760A5 (enExample) 2021-03-18

Family

ID=58462729

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019541330A Pending JP2020507760A (ja) 2017-01-31 2018-01-31 方法、アレイ、およびそれらの使用

Country Status (13)

Country Link
US (1) US20190382849A1 (enExample)
EP (1) EP3577464A1 (enExample)
JP (1) JP2020507760A (enExample)
KR (1) KR20190109422A (enExample)
CN (1) CN110325860A (enExample)
AU (1) AU2018214180A1 (enExample)
BR (1) BR112019015633A2 (enExample)
CA (1) CA3051968A1 (enExample)
GB (1) GB201701572D0 (enExample)
IL (1) IL268244A (enExample)
MX (1) MX2019008911A (enExample)
RU (1) RU2019123695A (enExample)
WO (1) WO2018141804A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008117067A2 (en) 2007-03-27 2008-10-02 Carl Arne Krister Borrebaeck Protein signature/markers for the detection of adenocarcinoma
CA3142634A1 (en) * 2019-07-03 2021-01-07 Crystal Bioscience Inc. Anti-b7-h3 antibody and methods of use thereof
KR102289278B1 (ko) * 2019-07-09 2021-08-13 주식회사 베르티스 췌장암 진단용 바이오마커 패널 및 그 용도
JP2023507369A (ja) * 2019-12-20 2023-02-22 メディミューン，エルエルシー グリピカン３を標的とするキメラ抗原受容体を用いて癌を治療する組成物及び方法
GB202010970D0 (en) 2020-07-16 2020-09-02 Immunovia Ab Methods, arrays and uses thereof
AU2022244125A1 (en) * 2021-03-26 2023-10-19 BioNTech SE Combination therapy with an anti-ca19-9 antibody and folfirinox in the treatment of cancer
CN113336851B (zh) * 2021-06-30 2021-12-24 徐州医科大学 新型全人源抗人b7h3抗体、包含所述抗体的组合物及其应用
CN120177800B (zh) * 2025-05-23 2025-10-10 四川大学 血液生物标志物cfp在制备急性胰腺炎诊断试剂的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130260388A1 (en) * 2010-09-09 2013-10-03 Beijing Cotimes Biotech Co., Ltd. Blood markers for diagnosing epithelium derived cancers and monoclonal antibodies thereof
JP2016537652A (ja) * 2013-11-11 2016-12-01 イムノヴィア・アクチエボラーグ 膵臓がんを決定するための方法、アレイおよびそれらの使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US8632983B2 (en) * 2005-04-15 2014-01-21 Van Andel Research Institute Biomarkers for pancreatic cancer and diagnostic methods
WO2008117067A2 (en) 2007-03-27 2008-10-02 Carl Arne Krister Borrebaeck Protein signature/markers for the detection of adenocarcinoma
GB201103726D0 (en) 2011-03-04 2011-04-20 Immunovia Ab Method, array and use thereof
GB201206323D0 (en) * 2012-04-10 2012-05-23 Immunovia Ab Methods and arrays for use in the same
GB201516801D0 (en) * 2015-09-22 2015-11-04 Immunovia Ab Method, array and use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130260388A1 (en) * 2010-09-09 2013-10-03 Beijing Cotimes Biotech Co., Ltd. Blood markers for diagnosing epithelium derived cancers and monoclonal antibodies thereof
JP2016537652A (ja) * 2013-11-11 2016-12-01 イムノヴィア・アクチエボラーグ 膵臓がんを決定するための方法、アレイおよびそれらの使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANNA SANDSTROM: "Plasma protein profiling in a stage defined pancreatic cancer cohort e Implications for early diagno", MOLECULAR ONCOLOGY, vol. 10, JPN6021010738, 12 July 2016 (2016-07-12), pages 1305 - 1316, ISSN: 0004844222 *

Also Published As

Publication number Publication date
US20190382849A1 (en) 2019-12-19
BR112019015633A2 (pt) 2020-03-17
KR20190109422A (ko) 2019-09-25
AU2018214180A1 (en) 2019-08-08
CA3051968A1 (en) 2018-08-09
IL268244A (en) 2019-09-26
GB201701572D0 (en) 2017-03-15
EP3577464A1 (en) 2019-12-11
CN110325860A (zh) 2019-10-11
RU2019123695A (ru) 2021-03-02
MX2019008911A (es) 2019-09-26
WO2018141804A1 (en) 2018-08-09

Similar Documents

Publication Publication Date Title
JP2020507760A (ja) 方法、アレイ、およびそれらの使用
US20220206004A1 (en) Method, array and use thereof
EP3353552B1 (en) Method and array for diagnosing pancreatic cancer in an individual
US11320436B2 (en) Methods, arrays and uses thereof
Cheng et al. Global gene expression and functional network analysis of gastric cancer identify extended pathway maps and GPRC5A as a potential biomarker
Afzal et al. PARP1: A potential biomarker for gastric cancer
US20170192004A1 (en) Methods and Arrays for Use in the Same
CN102472753A (zh) 基于组蛋白macroH2A同工型预测癌症复发风险的诊断方法
Di Paola et al. Interplay between WNT/PI3K-mTOR axis and the microbiota in APC-driven colorectal carcinogenesis: data from a pilot study and possible implications for CRC prevention
Kafle et al. Current state of knowledge on blood and tissue-based biomarkers for opisthorchis viverrini-induced Cholangiocarcinoma: a review of prognostic, predictive, and diagnostic markers
ES2332557A1 (es) Huella genomica para el pronostico de la evolucion de adenocarcinoma colorectal.
AU2020332349A1 (en) Protein panels for the early diagnosis/prognosis and treatment of aggressive prostate cancer
ES2897677T3 (es) Olfactomedina-4, neudesina y desmoplaquina como nuevos biomarcadores del cáncer de mama
EP4571314A1 (en) Multiple biomarker for cancer diagnosis and use thereof
Wu et al. Correlation Between Drug Sensitivity Profiles of Ex Vivo Expanded Circulating Tumor Cells and Clinical Treatment Response in Pancreatic Ductal Adenocarcinoma Patients
WO2022260166A1 (ja) 癌診断用キット及びその使用
CN117425827A (zh) 用于诊断癌症的试剂盒及其用途
WO2016060382A1 (ko) 췌장암 진단용 조성물 및 이를 이용한 췌장암 진단방법
WO2015092075A1 (en) Cers5 as a predictive variable of response to cancer therapy and in particular neoadjuvant cancer therapy
AU2012235883A1 (en) Cancer detection

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210201

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220401

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220808